These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 25862941

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
    Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD.
    BMC Pulm Med; 2015 Dec 29; 15():167. PubMed ID: 26714746
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
    Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, du Bois RM, Wells AU.
    Eur Respir J; 2010 Apr 29; 35(4):830-6. PubMed ID: 19840957
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Qiu M, Chen Y, Ye Q.
    Clin Respir J; 2018 Mar 29; 12(3):1084-1092. PubMed ID: 28332341
    [Abstract] [Full Text] [Related]

  • 10. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
    Konishi S, Arita M, Ito I, Tachibana H, Takaiwa T, Fukuda Y, Watanabe N, Tsubouchi K, Masuda G, Tanaka M, Kourogi Y, Kunimasa K, Nishiyama A, Iwasaku M, Ito A, Tokioka F, Yoshioka H, Hashimoto T, Ishida T.
    Intern Med; 2015 Mar 29; 54(22):2835-41. PubMed ID: 26567995
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Disease progression in idiopathic pulmonary fibrosis without pulmonary function impairment.
    Kondoh Y, Taniguchi H, Ogura T, Johkoh T, Fujimoto K, Sumikawa H, Kataoka K, Baba T, Colby TV, Kitaichi M.
    Respirology; 2013 Jul 29; 18(5):820-6. PubMed ID: 23489318
    [Abstract] [Full Text] [Related]

  • 13. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
    Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, Hopkins P, Keir G, Mahar A, Cooper W, Reynolds P, Haydn Walters E, Zappala C, Grainge C, Allan H, Macansh S, Corte TJ.
    BMC Pulm Med; 2018 Jan 25; 18(1):19. PubMed ID: 29370786
    [Abstract] [Full Text] [Related]

  • 14. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis.
    Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, Kohno N, Bonella F, Guzman J, Costabel U.
    Respir Med; 2014 Jul 25; 108(7):1031-9. PubMed ID: 24835074
    [Abstract] [Full Text] [Related]

  • 15. Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosis.
    Fahim A, Crooks MG, Wilmot R, Campbell AP, Morice AH, Hart SP.
    Respirology; 2012 Nov 25; 17(8):1247-52. PubMed ID: 22816375
    [Abstract] [Full Text] [Related]

  • 16. Predictors of acute exacerbation in biopsy-proven idiopathic pulmonary fibrosis.
    Kishaba T, Hozumi H, Fujisawa T, Nei Y, Enomoto N, Sugiura H, Kitani M, Suda T.
    Respir Investig; 2020 May 25; 58(3):177-184. PubMed ID: 32205147
    [Abstract] [Full Text] [Related]

  • 17. The serum KL-6 levels in untreated idiopathic pulmonary fibrosis can naturally decline in association with disease progression.
    Ishii H, Kushima H, Kinoshita Y, Fujita M, Watanabe K.
    Clin Respir J; 2018 Sep 25; 12(9):2411-2418. PubMed ID: 30015394
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.